Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes | Zendy

Anna R. Kahkoska | Zendy; Trine Julie Abrahamsen | Zendy; G. Caleb Alexander | Zendy; Tellen D. Bennett | Zendy; Christopher G. Chute | Zendy; Melissa Haendel | Zendy; Klara R. Klein | Zendy; Hemalkumar B. Mehta | Zendy; Joshua D. Miller | Zendy; Richard A. Moffitt | Zendy; Til Stürmer‎ | Zendy; Kajsa Kvist | Zendy; John B. Buse | Zendy; Timothy Q. Duong | Zendy

Open Access

Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes

Author(s) -

Anna R. Kahkoska,

Trine Julie Abrahamsen,

G. Caleb Alexander,

Tellen D. Bennett,

Christopher G. Chute,

Melissa Haendel,

Klara R. Klein,

Hemalkumar B. Mehta,

Joshua D. Miller,

Richard A. Moffitt,

Til Stürmer‎,

Kajsa Kvist,

John B. Buse,

Timothy Q. Duong

Publication year - 2021

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-0065

Subject(s) - medicine , dipeptidyl peptidase 4 , odds ratio , diabetes mellitus , glucagon like peptide 1 receptor , cohort study , cohort , type 2 diabetes , agonist , endocrinology , receptor

To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research